Clinical Trial Update: Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™ [Phase 4]

View source ↗

Summary

Phase 4 study assessing antibody persistence in children previously vaccinated with Infanrix Hexa or Infanrix-IPV/Hib; completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Disease
• Hepatitis B
• Pertussis
• Poliomyelitis
• Tetanus

Drugs mentioned

• Infanrix Hexa (DTPa-HBV-IPV/Hib)
• Infanrix IPV/Hib (Diphtheria, Tetanus, Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae type b vaccine (DTaP-IPV-Hib))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Tetanus, Poliomyelitis | Phase 4 | Status: COMPLETED | Results posted: 2016-12-29